Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Patient Advocate Carol Wiedmeyer supports HI HB 254 HD2

Mar 24/50SN Staff/ Advocacy Testimony

I am writing you today to express our support for HB 254 HD 2, which addresses patient and
physician notification during the substitution of a biosimilar and biologic product.

READ MORE

GHLF supports HI HB 254 HD2

Mar 24/50SN Staff/ Letters and Testimony

HB 254 HD 2 takes positive steps toward updating Hawaii law to cover biologics and biosimilars
in a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

READ MORE

GHLF supports KY SB 134

Mar 15/50SN Staff/ Letters and Testimony

SB 134 takes positive steps toward updating Kentucky law to cover biologics and biosimilars in
a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.

READ MORE

GHLF supports CT SB 313

Mar 07/50SN Staff/ Letters and Testimony

SB 313 takes positive steps toward updating Connecticut law to cover biologics and biosimilars
in a way that protects patients.

READ MORE

Victory in the USA

Mar 01/50SN Staff/ Victories

The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Inc.

READ MORE